Which comes first? new study aims to optimize AML treatment sequence
Disease control
Recruiting now
This phase II trial is for older adults with a specific type of acute myeloid leukemia (AML) that has IDH gene mutations. Researchers want to find out whether starting treatment with an IDH-targeted drug (ivosidenib or enasidenib) followed by standard therapy (azacitidine plus ve…
Phase: PHASE2 • Sponsor: Alice Mims • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC